Literature DB >> 3983884

Bronchodilator actions of xanthine derivatives administered by inhalation in asthma.

M J Cushley, S T Holgate.   

Abstract

The airway response to the inhalation of four alkyl xanthines was studied in 17 subjects with moderately severe asthma (mean FEV1 1.19 litres, 42% predicted). Theophylline (10 mg/ml), glycine theophyllinate (50 mg/ml), theophylline ethylenediamine (aminophylline 50 mg/ml), and diprophylline (125 mg/ml) were administered by nebulisation and the airway response was measured as percentage change from baseline of specific airway conductance (sGaw). All xanthine derivatives had an unpleasant taste and produced coughing at the onset of nebulisation. All four xanthines produced a significant increase in sGaw by comparison with saline placebo, with a maximum mean increase from baseline of 35% for theophylline, 40% for glycine theophyllinate, 60% for aminophylline, and 32% for diprophylline. Inhalation of 200 micrograms salbutamol from a metered dose inhaler produced an additional increase in sGaw of 149%. Thus alkyl substituted xanthines administered by inhalation to patients with asthma cause significant short lived bronchodilatation, but this effect is small compared with that of a conventional dose of an inhaled beta 2 adrenoceptor agonist.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3983884      PMCID: PMC460019          DOI: 10.1136/thx.40.3.176

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  [On the treatment of bronchial asthma with euphyllin aerosols (preliminary communication)].

Authors:  M P KRAMARENKO
Journal:  Klin Med (Mosk)       Date:  1961-01

2.  Clinical pharmacology of bronchospasmolytics in the asthmatic.

Authors:  R Aepli
Journal:  Helv Med Acta       Date:  1969-03

Review 3.  Therapeutic aerosols 2--Drugs available by the inhaled route.

Authors:  S W Clarke; S P Newman
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

4.  Chemotherapy for tuberculosis today.

Authors:  W W Stead; A K Dutt
Journal:  Am Rev Respir Dis       Date:  1982-03

5.  The bronchodilator action of theophylline aerosol in subjects with chronic airflow obstruction.

Authors:  A B Bohadana; R Peslin; D Teculescu; J M Polu; F Belleville; N Massin
Journal:  Bull Eur Physiopathol Respir       Date:  1980 Jan-Feb

6.  The value and safety of nebulized aminophylline in acute bronchial asthma.

Authors:  G E Horton
Journal:  J Tenn Med Assoc       Date:  1966-03

7.  [Efficacy of theophylline aerosols in obstructive lung diseases (author's transl)].

Authors:  D Kandt; H Ivainsky; I Sehrt
Journal:  Respiration       Date:  1981       Impact factor: 3.580

8.  A trial of aerosolized theophylline in relieving bronchospasm.

Authors:  B N Stewart; A J Block
Journal:  Chest       Date:  1976-06       Impact factor: 9.410

9.  Theophylline prescribing, serum concentrations, and toxicity.

Authors:  A A Woodcock; M A Johnson; D M Geddes
Journal:  Lancet       Date:  1983-09-10       Impact factor: 79.321

  9 in total
  3 in total

1.  Stimulatory Effects of KPR-A148 on Osteoblast Differentiation and Bone Regeneration.

Authors:  Soomin Lim; Ju Ang Kim; Taeho Lee; Jiwon Lim; Doohyun Lee; Sang-Hyeon Nam; Eui Kyun Park
Journal:  Tissue Eng Regen Med       Date:  2019-07-17       Impact factor: 4.169

Review 2.  Theophylline.

Authors:  Peter J Barnes
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-18

Review 3.  Xanthine scaffold: scope and potential in drug development.

Authors:  Nivedita Singh; Ashwinee Kumar Shreshtha; M S Thakur; Sanjukta Patra
Journal:  Heliyon       Date:  2018-10-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.